Publications by authors named "Michele Basche"

Claim this Profile
A
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
Gayle S Jameson, John T Hamm, Glen J Weiss, Carlos Alemany, Stephen Anthony, Michele Basche

Clin Cancer Res· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.
Laura Q M Chow, Daniel L Gustafson, Cindy L O'Bryant, Lia Gore, Michele Basche

Cancer Chemother Pharmacol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
Elaine T Lam, Cindy L O'Bryant, Michele Basche, Daniel L Gustafson, Natalie Serkova

Mol Cancer Ther· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
Laura Q M Chow, S Gail Eckhardt, Cindy L O'Bryant, Mary Kay Schultz, Mark Morrow, Michele Basche

Cancer Chemother Pharmacol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barriers to enrollment of elderly adults in early-phase cancer clinical trials.
Michele Basche, Anna E Barón, S Gail Eckhardt, Lodovico Balducci, Martha Persky

J Oncol Pract· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.
Michele Basche, Daniel L Gustafson, Scott N Holden, Cindy L O'Bryant, Lia Gore

Clin Cancer Res· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Lisa J Green, Philip Marder, Chad Ray, Carolyn A Cook, Susan Jaken, Michele Basche

Clin Cancer Res· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
Hiroyuki Kobayashi, S Gail Eckhardt, Jennifer A Lockridge, Mace L Rothenberg, Alan B Sandler, Michele L Basche

Cancer Chemother Pharmacol· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
Samir E Witta, Daniel L Gustafson, A Scott Pierson, Alexander Menter, Scott N Holden, Michele Basche

Clin Cancer Res· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of non-small-cell lung cancer in older persons.
Michele Basche, Karen Kelly

Oncology (Williston Park)· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis